Get the Stockscreener App
1.57
0.32%
0.005
Pre-market:
1.63
0.06
+3.82%
Inmune Bio Inc stock is traded at $1.57, with a volume of 383.82K.
It is up +0.32% in the last 24 hours and down -14.21% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$1.565
Open:
$1.6
24h Volume:
383.82K
Relative Volume:
0.82
Market Cap:
$41.74M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-0.9401
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
+3.29%
1M Performance:
-14.21%
6M Performance:
-78.16%
1Y Performance:
-70.93%
1-Day Range:
$1.5401
$1.60
1-Week Range:
$1.5199
$1.7516
52-Week Range:
$1.38
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.57 | 41.61M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Why INmune Bio Inc. stock could see breakout soonWeekly Loss Report & Daily Momentum Trading Reports - Newser
Can INmune Bio Inc. stock beat analyst upgradesStock Surge & Free Technical Confirmation Trade Alerts - Newser
Can INmune Bio Inc. stock sustain revenue growthJuly 2025 News Drivers & AI Powered Buy and Sell Recommendations - Newser
INmune Bio reports promising Alzheimer’s drug data at CTAD conference By Investing.com - Investing.com Canada
INmune Bio stock falls after new Alzheimer’s trial data By Investing.com - Investing.com UK
INmune Bio stock falls after new Alzheimer’s trial data - Investing.com
INmune Bio (INMB) Reveals Promising Phase 2 Neuroimaging Data for Alzheimer's Treatment - GuruFocus
INmune Bio (INMB) Reveals Promising Phase 2 Neuroimaging Data fo - GuruFocus
INmune Bio, Inc. Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595?s Evidence Base in High-Inflammation Alzheimer's Patients - MarketScreener
What drives INmune Bio Inc stock priceREITs Market Trends & Consistent High Yield Stocks - earlytimes.in
Inmune Bio announces new executive employment agreements with compensation details - Investing.com Nigeria
Inmune Bio announces new executive employment agreements with compensation details By Investing.com - Investing.com South Africa
Inmune Bio Announces New Executive Employment Agreements - TipRanks
How INmune Bio Inc. stock performs in high volatility marketsTrade Volume Summary & Technical Pattern Alert System - moha.gov.vn
Block Trades: Why analysts upgrade INmune Bio Inc. stockTrade Analysis Report & High Win Rate Trade Alerts - BỘ NỘI VỤ
INmune Bio Inc Stock Analysis and ForecastStock Buy Signals & Minimal Capital Appreciation - earlytimes.in
Is INmune Bio Inc. stock positioned for long term growth2025 Technical Overview & Technical Buy Zone Confirmation - newser.com
Analyzing recovery setups for INmune Bio Inc. investorsMarket Sentiment Report & Verified Swing Trading Watchlist - newser.com
Is INmune Bio Inc. a candidate for recovery playWeekly Gains Report & Consistent Profit Alerts - newser.com
Why INmune Bio Inc. stock is a value investor pickRisk Management & Daily Entry Point Alerts - newser.com
Heatmap analysis for INmune Bio Inc. and competitorsWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Short interest data insights for INmune Bio Inc.Market Trend Review & Verified Technical Signals - newser.com
How INmune Bio Inc. stock benefits from global expansionMarket Sentiment Summary & Reliable Price Action Trade Plans - newser.com
Candlestick signals on INmune Bio Inc. stock today2025 Momentum Check & Expert Curated Trade Ideas - newser.com
INmune Bio (INMB) Stock Analysis Report | Financials & Insights - Benzinga
INmune Bio Inc. (INMB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Does INmune Bio Inc. stock trade at a discount to peers2025 Market Outlook & Growth Focused Investment Plans - newser.com
[Form 4] Inmune Bio, Inc. Insider Trading Activity - Stock Titan
INmune Bio Approves Option Repricing Proposal - TipRanks
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
INmune Bio, Inc. Announces Presentations at 18th Clinical Trials on Alzheimer’s Disease Conference - Quiver Quantitative
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference - Bluefield Daily Telegraph
INmune Bio (INMB) plans XPro1595 Phase 2 Alzheimer’s and EMACC talks at 18th CTAD - Stock Titan
How INmune Bio Inc. stock reacts to Fed rate cutsJuly 2025 Technicals & Expert Curated Trade Setup Alerts - newser.com
INmune Bio Inc.Common stock (NQ: INMB - FinancialContent
Statistical indicators supporting INmune Bio Inc.’s strengthShare Buyback & AI Powered Market Trend Analysis - newser.com
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):